G

    Gilead Sciences Inc (GILD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $146.34
    +0.66 (+0.45%)

    Market Cap: $180.64B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    +4.92%
    Streak
    10 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$2.15
    Range$1.90 - $2.68
    20 analysts
    EPS Revisions
    3
    0
    7d
    5
    9
    30d
    EPS Estimate Drift
    90d ago$1.78-17.5%
    60d ago$2.08-3.5%
    30d ago$2.22+3.2%
    7d ago$2.15+0.0%
    Current$2.15
    Revenue Consensus
    $7.8B
    Range$7.5B - $8.1B
    19 analysts
    Dec 31, 2026
    EPS Consensus$2.76
    Range$2.57 - $3.17
    25 analysts
    Revenue Consensus
    $8.6B
    Range$8.2B - $9.1B
    24 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.76---
    Sep 26EST
    		-$2.15---
    Jun 26
    		$-6.75$-7.07+4.53%Beat-435.8%
    Mar 26
    		$2.03$1.91+6.28%Beat+12.2%
    Dec 25
    		$1.86$1.81+2.76%Beat-2.1%
    Sep 25
    		$2.47$2.14+15.42%Beat+22.3%
    Jun 25
    		$2.01$1.95+3.08%Beat+0.0%
    Mar 25
    		$1.81$1.78+1.69%Beat+237.1%
    Dec 24
    		$1.90$1.70+11.73%Beat+10.5%
    Sep 24
    		$2.02$1.55+30.32%Beat-11.8%
    Jun 24
    		$2.01$1.60+25.63%Beat+50.0%
    Mar 24
    		$-1.32$-1.52+13.16%Beat-196.4%
    Dec 23
    		$1.72$1.76-2.27%Miss+3.0%
    Sep 23
    		$2.29$1.92+19.27%Beat+20.5%
    Jun 23
    		$1.34$1.64-18.29%Miss-15.2%
    Mar 23
    		$1.37$1.54-11.04%Miss-35.4%
    Dec 22
    		$1.67$1.51+10.60%Beat+142.0%
    Sep 22
    		$1.90$1.43+32.87%Beat-28.3%
    Jun 22
    		$1.58$1.52+3.95%Beat-15.5%
    Mar 22
    		$2.12$1.81+17.13%Beat+1.9%
    Dec 21
    		$0.69N/A-56.60%Miss-68.5%
    Sep 21
    		$2.65$1.78+48.88%Beat+25.6%
    Jun 21
    		$1.87$1.75+6.86%Beat+68.5%
    Mar 21
    		$2.08$2.11-1.42%Miss+23.8%
    Dec 20
    		$2.19$2.15+1.86%Beat+68.5%
    Sep 20
    		$2.11$1.89+11.64%Beat+20.6%
    Jun 20
    		$1.11$1.45-23.45%Miss-39.0%
    Mar 20
    		$1.68$1.56+7.69%Beat-4.5%
    Dec 19
    		$1.30$1.67-22.16%Miss-9.7%
    Sep 19
    		$1.75$1.73+1.16%Beat-4.9%
    Jun 19
    		$1.82$1.71+6.43%Beat-4.7%
    Mar 19
    		$1.76$1.60+10.00%Beat+18.9%
    Dec 18
    		$1.44$1.69-14.79%Miss-19.1%
    Sep 18
    		$1.84$1.63+12.88%Beat-18.9%
    Jun 18
    		$1.91$1.56+22.44%Beat-25.4%
    Mar 18
    		$1.48$1.67-11.38%Miss-33.6%
    Dec 17
    		$1.78$1.67+6.59%Beat-34.1%
    Sep 17
    		$2.27$2.13+6.57%Beat-17.5%
    Jun 17
    		$2.56$2.17+17.97%Beat-
    Mar 17
    		$2.23$2.28-2.19%Miss-
    Dec 16
    		$2.70$2.60+3.85%Beat-
    Sep 16
    		$2.75$2.83-2.83%Miss-

    Dividends

    Dividend Metrics

    Yield2.20%
    Annual/Share$3.22
    Payout Ratio29.53%
    Frequency4
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+2.67%
    5Y CAGR+3.04%
    View GILD's full dividend history

    Key Metrics

    Valuation
    P/E Ratio-375.23EV/EBITDA115.17x
    Price/FCF14.05xFCF Yield7.12%
    Profitability
    Profit Margin-10.60%Operating Margin33.70%
    ROE-20.70%ROIC28.42%
    Financial Health
    Debt/Equity2.22xInterest Coverage10.57x
    Current Ratio1.27xQuick Ratio1.09x
    Trading Statistics
    Beta0.34Avg Volume6.34M
    52-Week High$155.3852-Week Low$106.44

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$146.51
    SMA 20$140.81
    SMA 50$134.55
    SMA 200$133.00
    EMA 10$145.34
    EMA 20$142.06
    EMA 50$137.01
    EMA 200$131.11

    MACD

    Line: 4.09Signal: 3.73Hist: 0.37

    ADX

    ADX: 37.9+DI: 26.8-DI: 13.1

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down12.0
    PSAR$141.59

    Bollinger Bands

    Upper Band$153.42
    Lower Band$128.21
    %B Position1791%(Upper)
    Band Width0.72

    RSI (14-Day)

    Neutral
    62.2

    Momentum Oscillators

    Stoch %K84.4
    Stoch %D89.5
    Williams %R-20.1
    ROC (10d)5.3%
    Momentum7.42
    CCI (20d)59.6
    MFI (14d)69.3

    Volatility Measures

    ATR (14d)$3.82(2.6%)
    StdDev (20d)6.30
    Hist Vol27.9%(Moderate)

    Volume Flow

    VWAP$145.58
    OBV141.2M
    AD Line-2.2B
    CMF (20d)0.289

    Volume Metrics

    Avg Vol (20d)6.3M
    Vol Ratio1.0x
    VWMA (20d)$139.73

    Pivot Points

    R3$153.06
    R2$151.27
    R1$148.47
    Pivot Point$146.68
    S1$143.88
    S2$142.09
    S3$139.29

    Advanced Oscillators

    TSI29.78
    Ultimate Osc65.4
    KST101.41

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.80B$6.96B$7.92B$7.77B$7.08B$6.67B$7.57B$7.54B$6.95B$6.69B$7.11B$7.05B
    Cost of Revenue$1.58B$1.45B$1.62B$1.57B$1.50B$1.54B$1.58B$1.57B$1.54B$1.55B$2.09B$1.56B
    Gross Profit$6.22B$5.51B$6.30B$6.20B$5.58B$5.13B$5.99B$5.97B$5.41B$5.13B$5.02B$5.49B
    Operating Expenses$16.62B$2.93B$4.32B$2.87B$3.11B$2.89B$3.54B$5.08B$2.77B$9.46B$3.41B$2.86B
    R&D$12.95B$1.48B$2.12B$1.52B$1.55B$1.63B$1.63B$1.90B$1.39B$5.65B$1.75B$1.55B
    SG&A$1.92B$1.45B$1.79B$1.36B$1.36B$1.26B$1.91B$1.43B$1.38B$1.38B$1.61B$1.31B
    Operating Income$-10,394,000,000$2.59B$1.98B$3.33B$2.47B$2.24B$2.45B$888.00M$2.64B$-4,322,000,000$1.61B$2.62B
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$247.00M$240.00M$254.00M$256.00M$254.00M$260.00M$248.00M$238.00M$237.00M$254.00M$252.00M$232.00M
    Income Before Tax$-10,254,000,000$2.58B$2.08B$3.64B$2.43B$1.65B$2.17B$956.00M$2.05B$-4,486,000,000$1.65B$2.32B
    Income Tax Expense$242.00M$559.00M$-105,000,000$589.00M$468.00M$334.00M$385.00M$-297,000,000$438.00M$-315,000,000$236.00M$146.00M
    Net Income$-10,496,000,000$2.02B$2.18B$3.05B$1.96B$1.31B$1.78B$1.25B$1.61B$-4,170,000,000$1.42B$2.17B
    EBITDA$-9,309,000,000$3.51B$3.02B$4.58B$3.37B$2.60B$3.11B$1.88B$2.98B$-3,541,000,000$2.59B$3.23B
    EBIT$-10,007,000,000$2.82B$2.33B$3.90B$2.68B$1.91B$2.42B$1.19B$2.29B$-4,231,000,000$1.90B$2.55B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

    Quality meets catalyst: Two regulatory wins in 5 days. Dupixent's AFRS approval + garetosmab Priority Review. Quality Score 98/100. The business is strengthening while the stock trades near fair value. The honest valuation: At $789, REGN is ~1% above Vulcan's $778 BFV. Not cheap. Not expensive. The market has priced in the base case, leaving alpha entirely in when you buy not if. Dupixent is a compounding machine: Seven US indications and growing, co-commercialized with Sanofi. This isn't just an eczema drug, it's a type-2 inflammation platform that funds REGN's entire R&D pipeline. Fortress balance sheet, real tail risk: D/E of 0.1, 120x interest coverage, Altman Z of 7.8. Yet the 5-year max drawdown is -59.7%. Quality doesn't prevent drawdowns. The alpha zone: Buy zone $715–$730 (~9% pullback). Strong buy $625. Current price above both. Set alerts. No chasing. The patient investor wins here.

    Unknown Author
    •
    2/27/26
    •
    155
    Biotech
    BioPharma
    Also mentions:
    SNY
    AMGN
    TMDX
    GILD

    Part 2 of 3: The Night the Organ Monopoly Proved It Was Real

    Tonight's earnings confirmed the thesis: Q4 revenue $160.8M (+32%), FY $605.5M (+37%), 5,139 OCS cases (+38%), 2026 guidance $727M–$757M. TMDX has graduated from speculative disruptor to verified logistics monopoly. The 22-aircraft fleet is the moat: NOP bundled revenue converts device sales into recurring per-case logistics contracts at 60% gross margins. Building this fleet is what the market punished in 2023 and what it's reprici ROIC 12.1% now exceeds WACC 10.2% (+190 bps spread). This was negative during fleet buildout. Value creation is now confirmed, not projected. Healthcare Barbell context: (GILD) Part 1 is the income anchor, low beta, undervalued, 4%+ yield. (TMDX is the growth compounder. (REGN) Part 3 is the pipeline optionality. Three positions, three roles, one coherent thes

    Unknown Author
    •
    2/25/26
    •
    127
    healthcare-innovation
    Healthcare Stocks
    Also mentions:
    GILD
    REGN

    Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To

    Gilead's $14.3B Biktarvy franchise grew 7% YoY in 2025, proving HIV isn't ex-growth. Total revenues hit $29.4B. The base business alone justifies ~$150 fair value. Yeztugo (twice-yearly HIV prevention) expands TAM from diagnosed patients to at-risk populations. FDA approved June 2025. $800M combined lenacapavir guide for 2026. Arcellx acquisition ($7.8B) adds anito-cel CAR-T for multiple myeloma. FDA decision Dec 23, 2026. Logical Kite extension, but differentiation burden is real. At ~17x forward EPS ($8.45-$8.85 guided), you pay fair value for the base and get oncology pipeline optionality essentially free. 2.1% yield while you wait. Vulcan scores: 93 Overall, 93 Value, 88 Quality, 95 Sentiment. Altman Z 4.6, Piotroski F 7, ROIC 19.6%, 78.7% gross margins. Fortress fundamentals. Part 1 of the Healthcare Barbell series: GILD anchors with defensive cash flows (0.37 beta). Part 2 (TMDX) and Part 3 (REGN) incoming. Invalidation: Biktarvy YoY declines in two consecutive quarters or EPS guides lower.

    Unknown Author
    •
    2/24/26
    •
    119
    Healthcare Stocks
    healthcare-innovation
    Also mentions:
    TMDX
    REGN
    JNJ

    Eight Weeks in the Dark: What GNG Quant's Live Forward-Alpha Test Actually Revealed

    8 of 9 weekly 5-day windows beat the S&P 500 (89% hit rate), averaging +1.34% alpha per 5-day period. The one clear miss was 2026-01-23 (both surfaces negative), but subsequent runs snapped back positive. 21-day results are the standout: 5 of 5 windows positive, averaging +5.22% alpha vs the S&P 500. Compounding the 5-day windows implies ~+12.61% beating the S&P500 soundly!

    Unknown Author
    •
    2/24/26
    •
    207
    Quant
    Also mentions:
    GILD
    NVDA

    Pfizer: The 6% Yield Hiding Behind a Post-Pandemic Hangover

    Pfizer trades at 9.6x forward earnings with 6.3% yield; non-COVID portfolio grew 6% operationally in 2025, but market still prices post-pandemic discount GAAP payout ratio of 98.8% is misleading; on adjusted EPS of $3.22, actual payout is 53%. The $4.4B Seagen impairment distorts GAAP picture Metsera obesity pipeline (Phase 2b: 12.3% weight loss, monthly dosing) is unpriced optionality at current multiples; ten Phase 3 trials launch 2026 Morningstar cut fair value from $34 to $32 post-Q4; Stock Rover FV $34.57. Blended upside of 13-16% before dividends in base case Quality Score 85/100, Piotroski 7, Beneish M-Score -2.38. ROIC-WACC spread positive at +190 bps. Balance sheet is not the risk here Five explicit risks quantified: GAAP payout tightness, $1.5B LOE headwind, negative revision momentum, Metsera execution risk, policy headwinds Conditional BUY for income/value accounts with staged sizing at 0.5-1.0%; trim at $33-36; invalidation on dividend cut or two sub-$0.65 adj EPS quarters

    Unknown Author
    •
    2/12/26
    •
    150
    Income Investing
    value investing
    Also mentions:
    MRK
    BMY
    GILD
    ABBV

    Government Contracts

    Gov Obligations (TTM)
    -$9.51M
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    3
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

    Gilead Sciences, Inc. announced that its executives will present at three investor conferences in September 2026: the Wells Fargo Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley Global Healthcare Conference. Live webcasts of these presentations will be available on the company's investors page, with replays accessible for at least 30 days. Gilead Sciences is a biopharmaceutical company focused on developing medicines for life-threatening diseases like HIV, viral hepatitis, COVID-19, and cancer.

    Gilead Sciences•8/26/26•
    Neutral

    Gilead (NASDAQ: GILD) director to sell 18,000 shares

    Gilead Sciences director Anthony Welters plans to sell 18,000 shares of common stock, valued at $2,677,860.00, through Morgan Stanley Smith Barney LLC Executive Financial Services on or after August 26, 2026. This sale follows the exercise of stock options for cash and is being conducted under Rule 144. The Form 144 filing indicates a neutral impact and sentiment regarding this transaction.

    Stock Titan•8/26/26•
    Neutral

    Man Group plc Invests $156.06 Million in Gilead Sciences, Inc. $GILD

    Man Group plc recently acquired 1,235,196 shares of Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximately $156.06 million, representing about 0.10% of the biopharmaceutical company's stock. Several other institutional investors also adjusted their positions in GILD. Analysts currently have a "Moderate Buy" rating on the stock with an average price target of $158.04.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    Roberts Glore & Co. Inc. IL Makes New $1.25 Million Investment in Gilead Sciences, Inc. $GILD

    Roberts Glore & Co. Inc. IL has made a new $1.25 million investment in Gilead Sciences, Inc., purchasing 9,885 shares during the second quarter. Institutional investors hold a significant 83.67% stake in the company. Analysts have a "Moderate Buy" consensus rating with an average price target of $158.04, following strong quarterly revenue and a declared dividend.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    Jupiter Topco LLC Buys New Stake in Gilead Sciences, Inc. $GILD

    Jupiter Topco LLC has acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD), purchasing over 3.5 million shares valued at approximately $448 million during the second quarter. This makes Jupiter Topco LLC a significant institutional investor, owning about 0.29% of the biopharmaceutical company. Other institutional investors have also adjusted their holdings, while company insiders, including the CFO, have recently sold shares.

    MarketBeat•8/26/26•
    Neutral

    Frequently Asked Questions About GILD

    What is GILD's current dividend yield?
    Gilead Sciences Inc (GILD) has a current dividend yield of 2.20%.
    Does GILD pay dividends?
    Yes, Gilead Sciences Inc pays dividends with a current yield of 2.20%.
    What is GILD's market cap?
    Gilead Sciences Inc (GILD) has a market capitalization of $180.64B with a current stock price of $146.34.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In